The pre- and post-treatment ALT, AST, and HCV RNA levels of the 50 HCV patients, and the different subgroups (CH, cirrhosis, and HCC), were compared and, as expected due to the different stages of liver damage, the variation was statistically significant (p < 0.05) (Table 1). This evidence concerns the gene GPT and hepatocellular carcinoma.